Juliana Eujung Park

Juliana Eujung Park

Sanofi US - New Jersey / United States
Medical and Health Sciences / Pediatrics and Child Health
AD Scientific Index ID: 5541483
-
person_outline Juliana Eujung Park's MOST POPULAR ARTICLES
1-) Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3 …G de Bruyn, J Wang, A Purvis, MS Ruiz, H Adhikarla, S Alvi, MI Bonaparte, ...EClinicalMedicine 62, 2023202023
2-) Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9–50 years (CYD65): A randomised, controlled, phase 2 …DL Coronel-MartÍnez, J Park, E López-Medina, MR Capeding, ...The Lancet Infectious Diseases 21 (4), 517-528, 2021162021
3-) Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion …J Park, S Archuleta, MLH Oh, LPC Shek, J Jin, M Bonaparte, C Frago, ...Human Vaccines & Immunotherapeutics 16 (3), 523-529, 2020102020
4-) Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9–50 years: a randomised, controlled …DL Coronel-Martinez, J Park, E López-Medina, MR Capeding, ...The Lancet Infectious Diseases 22 (6), 901-911, 202282022
5-) Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studiesX Liu, J Park, S Xia, B Liang, S Yang, Y Wang, O Syrkina, N Lavis, S Liu, ...Human Vaccines & Immunotherapeutics 18 (6), 2132798, 202272022